arrow_back Trending Legislation
Share share

Lower Epinephrine Costs: Ending High Prices for Life-Saving Medication

This new act aims to reduce the cost of epinephrine delivery systems (like EpiPens) for individuals with health insurance. It means health plans cannot apply deductibles or charge more than $60 per package of two systems, making this life-saving medication more accessible.
Key points
Maximum out-of-pocket cost for two epinephrine delivery systems (e.g., EpiPen) will be $60 for insured individuals.
Health plans will not be able to apply deductibles for these medications.
Any cost-sharing payments made will count towards annual out-of-pocket maximums.
Changes will apply to plan years beginning on or after January 1, 2026.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
EPIPEN Act
Print number: HR 5139
Sponsor: Rep. Frost, Maxwell [D-FL-10]
Process start date: 2025-09-04
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Lower Epinephrine Costs: Ending High Prices for Life-Saving Medication

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5139.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-04.

What are the main provisions?

Key points include:

  • Maximum out-of-pocket cost for two epinephrine delivery systems (e.g., EpiPen) will be $60 for insured individuals.
  • Health plans will not be able to apply deductibles for these medications.
  • Any cost-sharing payments made will count towards annual out-of-pocket maximums.
  • Changes will apply to plan years beginning on or after January 1, 2026.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Frost, Maxwell [D-FL-10].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of HR 5139

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health